CCT6A is a structurally conserved core subunit of the eukaryotic CCT/TRiC complex, which participates in ATP-dependent protein folding, cytoskeletal dynamics and stress-responsive adaptation. According to the abstract, these functions are linked to cellular homeostasis. The review examines evidence that CCT6A can act as a multifunctional oncogenic driver in malignancies including colorectal cancer and hepatocellular carcinoma, with reported associations involving metabolic reprogramming, stabilization of oncoproteins and immunosuppression.

The abstract further reports that CCT6A overexpression correlates with aggressive phenotypes, therapeutic resistance and poor prognosis. On this basis, the authors position CCT6A as a candidate diagnostic and prognostic biomarker. These are research associations rather than evidence of an established clinical test or treatment, and the abstract does not specify the populations, sample sizes or effect estimates underlying the correlations. The review also considers CCT6A’s contribution to autoimmune diseases, pulmonary fibrosis and acute kidney injury, assessing its relevance beyond oncology.

Major therapeutic challenges identified in the abstract include context-dependent signaling mechanisms, the absence of subunit-specific inhibitors and the need to balance CCT6A targeting with preservation of CCT/TRiC complex function. The authors propose targeted therapeutic frameworks intended to refine precision medicine across disease settings, but the abstract does not report completed clinical trials, human treatment outcomes or a validated CCT6A-targeted therapy. Because only an abstract-level preview is available, the scope and limitations of this report are based solely on the published abstract rather than an assessment of the complete review.

Subject of Research: Review of CCT6A biomarker potential and therapeutic challenges across cancer and other diseases

Article Title: The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond

Article References: Du, R.-H., Cheng, Y., Ren, Z.-P., Li, S., Yuan, B.-W., Wei, X.-N., & Yan, S.-Y. (2026). The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond. Molecular Biology Reports, 53(1), Article 1596. https://doi.org/10.1007/s11033-026-12766-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12766-y

Keywords: CCT6A, biomarker, cancer, therapeutic target, CCT/TRiC complex, oncology, precision medicine, disease mechanisms, paradigm, potential, therapeutic, challenges

A research team led by Takako Kihara of the Department of Diagnostic Pathology at Hyogo Medical University School of Medicine in Japan, working with colleagues in Japan and China, now reports evidence that a single gap junction protein may help explain the poor prognosis of small intestinal GISTs. In a study published in Pathology and Oncology Research, the investigators show that Connexin 43, or Cx43, a four-pass transmembrane protein that assembles into hemichannels and gap junctions, enhances the liver metastatic ability of GIST cells in living animals. The work builds on the team’s earlier finding that most small intestinal GISTs express high levels of Cx43, while gastric GISTs show minimal expression of this protein.

Cx43 is the most ubiquitously expressed and extensively studied connexin in human tissues. Six Cx43 molecules form a hemichannel, and two paired hemichannels create a gap junction, a structure essential for transmitting ions, small molecules, and metabolites between cells. In cancer biology, Cx43 plays a dual role that varies by tumor type and stage. In colorectal and pancreatic cancer it acts as a tumor suppressor, whereas in breast cancer, gastric cancer, melanoma, and ovarian cancer it is considered a tumor promoter, with metastatic lesions showing elevated Cx43 expression at both protein and mRNA levels compared with primary lesions. In breast cancer, Cx43 staining is absent in non-invasive ductal carcinoma but appears in the cytoplasm and membrane of invasive tumors, and it intensifies further in lymph node metastases. A recent study in colorectal cancer found that Cx43 on the cell membrane suppresses tumor progression, but its translocation to the nucleus is associated with metastatic spread.

To test whether Cx43 drives the metastatic behavior characteristic of small intestinal GISTs, the researchers compared two versions of the GIST-T1 cell line. The original GIST-T1 cells, derived from a metastatic pleural tumor of a gastric GIST in a 47-year-old Japanese woman with a heterozygous KIT exon 11 mutation, express minimal Cx43 and represent gastric GISTs. The team engineered a second line, GIST-T1-Cx43, by transfecting full-length Cx43 cDNA into these cells and selecting stable clones with Zeocin, creating cells with high Cx43 expression that model small intestinal GISTs. Western blot analysis confirmed that Cx43 protein levels were significantly higher in the engineered cells.

The centerpiece of the study was a newly developed in vivo liver metastasis xenograft model. Because GISTs are typically indolent tumors, establishing a liver metastasis model has proven challenging, and no such model had previously been documented. Thirteen female NOG mice, an immunodeficient strain lacking functional T, B, and natural killer cells, were anesthetized with isoflurane, and 2 million GIST cells were injected into the spleen with a 29-gauge needle. Cells entering the splenic vein travel through the portal circulation to the liver, seeding metastatic foci. Four weeks after intrasplenic injection, the livers were excised, sectioned at 2-millimeter intervals, and examined histologically with hematoxylin and eosin staining, counting any cluster of three or more tumor cells as one metastatic focus.

The results were striking. Mice transplanted with GIST-T1-Cx43 cells developed 2.53 times more hepatic metastatic foci than mice receiving the original GIST-T1 cells, a difference that reached statistical significance at p = 0.010. A single outlier in each group was identified with Grubbs’ test and excluded after confirming data normality. This in vivo finding provides direct evidence that elevated Cx43 expression enhances the liver metastatic potential of GIST cells, corroborating the clinical observation that small intestinal GISTs, which naturally express high Cx43, carry a higher risk of distant metastasis.

Conventional in vitro experiments painted a more nuanced picture of how Cx43 reshapes tumor cell behavior. When seeded at low density and incubated for seven days, GIST-T1-Cx43 cells grew significantly more slowly than the original cells, with suppressed proliferation at p < 0.001. Yet the same cells showed a 3.43-fold increase in migration through uncoated transwell membranes (p < 0.001) and a 1.70-fold increase in invasion through Matrigel-coated chambers (p = 0.036). Cx43 thus appears to trade proliferative capacity for motility, a hallmark of the metastatic phenotype.

The team then examined how Cx43 affects the interaction between tumor cells and vascular endothelium, a critical step in the metastatic cascade. In a static adhesion assay, Calcein-AM-labeled GIST-T1-Cx43 cells adhered to confluent monolayers of human umbilical vein endothelial cells 1.67 times more than the original cells (p < 0.001). In a transendothelial migration assay, the engineered cells migrated through the endothelial monolayer 1.56 times more (p < 0.001). These findings parallel the team’s earlier work on CADM1, another surface molecule predominantly expressed in small intestinal GISTs, which similarly promoted endothelial adhesion and transmigration while suppressing proliferation.

Western blot analysis of KIT downstream signaling revealed a mechanistic clue. MAPK phosphorylation was activated, while AKT phosphorylation was suppressed, in GIST-T1-Cx43 cells compared with the original line, indicating significant activation of the RAS-RAF-MAPK pathway. This pathway is crucial for tissue remodeling and cell migration, both essential for tumor invasion and metastasis, and its aberrant activation in cancer promotes tumor growth and metastatic spread. The findings suggest that Cx43 may enhance liver metastasis of GIST cells by shifting signaling toward this pro-migratory cascade.

The study’s implications extend to therapy. The authors propose that an antibody targeting Cx43 could inhibit small intestinal GIST metastasis by suppressing migration, invasion, tumor-endothelial adhesion, and transendothelial migration. Their recent work showed that an antibody-drug conjugate targeting CADM1 exhibits significant antitumor effects on GIST cells with high CADM1 expression, and they suggest that ADCs targeting both Cx43 and CADM1 may offer even greater efficacy. The study has limitations: the in vivo model addressed liver metastasis but not peritoneal dissemination, the effect of Cx43 on other surface adhesion molecules was not thoroughly investigated, and the role of Cx43 in angiogenesis and immune evasion within the tumor microenvironment remains unexplored. Nevertheless, by establishing the first documented GIST liver metastasis model and validating it in vitro, the team has identified Cx43 as a potential novel therapeutic target for inhibiting metastasis in the GIST subtype that needs it most.

Subject of Research: Oncology

Article Title: Connexin 43 enhances liver metastatic ability of GIST cells in vivo

Article References: Kihara, T., Yuan, J., Yamasaki, T., Yoshida, M., Ohkouchi, M., Nakaya-Hashikura, Y., Kimura, N., Hyodo, K., Ohe, C., & Hirota, S. (2026). Connexin 43 enhances liver metastatic ability of GIST cells in vivo. Pathology & Oncology Research, 32, Article 1612383. https://doi.org/10.3389/pore.2026.1612383

Image Credits: AI Generated

DOI: 10.3389/pore.2026.1612383

Keywords: GIST, Connexin 43, liver metastasis, small intestinal tumors, gap junctions, RAS-RAF-MAPK, cancer metastasis, therapeutic target, Connexin, enhances, liver, metastatic

G0S2 is, by protein standards, remarkably minimal. It encodes a short peptide first recognized for its role at the boundary between the resting G0 phase and the proliferative G1 phase of the cell cycle, hence its name. Over the years, however, studies have tied the protein to a startling range of processes: lipid metabolism, where it binds and inhibits adipose triglyceride lipase; inflammation, where it has been linked to signaling cascades involving nuclear factor of activated T cells; and, increasingly, cell death. What has remained murky is precisely how G0S2 participates in apoptosis, particularly in the context of cancer, where tumor cells routinely suppress the very pathways that would otherwise eliminate them. The new study set out to close that gap by asking a straightforward question: what happens to the protein landscape of an organism when G0S2 is forced into overexpression?

The methodological heart of the paper is proteomics, the large-scale inventory and comparison of proteins in a biological sample. Rather than inferring what G0S2 does from gene expression alone, which can be misleading because messenger RNA levels often fail to track protein abundance, the team directly measured the protein complement of G0S2-overexpressing mice and compared it against controls. From the resulting data they performed functional annotations using Gene Ontology frameworks, pathway analysis through the Kyoto Encyclopedia of Genes and Genomes, and protein-protein interaction network mapping. These computational lenses converged on a consistent signal: among the molecular programs perturbed by G0S2 overexpression, apoptosis stood out, with multiple components of the death-signaling machinery shifting in abundance in ways consistent with an activated cell death program.

The specific players matter. BAX, or BCL2-associated X protein, is a pro-apoptotic member of the BCL-2 family that, when activated, permeabilizes the outer mitochondrial membrane, releasing factors that tip a cell into irreversible self-destruction. Caspase3 is the executioner enzyme of the pathway, a protease that once cleaved and activated systematically dismantles the cell’s structural and regulatory components. FADD, the Fas-associating protein with a novel death domain, sits at the junction of death receptor signaling, transmitting suicidal commands from the cell surface inward. Finding all three altered in G0S2-overexpressing tissue suggested that the small protein was not merely brushing against the apoptosis machinery but engaging it at multiple points, with the BAX-to-Caspase3 sequence emerging as the apparent conduit through which G0S2 exerts its effect.

Crucially, the researchers did not stop at correlation. To verify that apoptosis was genuinely occurring, they deployed TUNEL staining, a technique that flags the fragmented DNA characteristic of dying cells, alongside immunohistochemistry to visualize protein changes in tissue context, and molecular genetic strategies to interrogate the pathway’s behavior. Together, these validation experiments supported the central claim: G0S2 overexpression is associated with measurable, verifiable cell death, and the BAX/Caspase3 pathway is the mechanism through which the protein promotes it. In the language of the paper’s conclusion, G0S2 is implicated in apoptosis specifically through this axis, a finding the authors suggest could illuminate therapeutic strategies for diseases tied to apoptosis, inflammation and cancer.

The implications for hepatocellular carcinoma, the most common form of primary liver cancer, are what give the work its urgency. Hepatocellular carcinoma is a devastating malignancy, frequently diagnosed late and often arising in livers already damaged by hepatitis infection, alcohol-related injury or metabolic disease. One of the hallmarks of cancer, recognized for decades, is the ability of tumor cells to resist apoptosis, allowing damaged and genetically unstable cells to survive, proliferate and spread. If G0S2 functions as a pro-apoptotic influence, then tumors might benefit from silencing or downregulating it, and restoring its activity could, in principle, re-sensitize malignant cells to self-destruction. The authors frame the protein as a potential therapeutic target for precisely this reason, though the path from a mouse proteomics experiment to a clinical strategy is long and demanding.

It is worth situating the finding within the broader history of G0S2 research, which has been accumulating suggestive evidence for years. The protein has been reported to interact with signaling systems as varied as peroxisome proliferator-activated receptor agonists and retinoids, both of which have metabolic and differentiation-related effects on cells. It has appeared in studies of chronic kidney disease, subarachnoid hemorrhage and stress signaling, and it has been connected to networks involving mTOR, hypoxia-inducible factor 1-alpha and the DNA damage response. What the new study adds is a mechanistic anchor: a defined pathway, BAX/Caspase3, through which the protein’s apoptotic influence can be understood and, eventually, manipulated. That kind of mechanistic clarity is what transforms a protein from a statistical association in high-throughput data into a credible biological hypothesis.

The proteomic approach itself deserves attention, because it reflects a wider shift in how cancer biology is being done. Genome and transcriptome studies have catalogued countless genetic alterations in tumors, but proteins are the molecules that actually execute cellular behavior, and their regulation is layered with modifications, interactions and turnover dynamics that nucleic acid measurements cannot capture. By profiling the entire protein complement of G0S2-overexpressing tissue and then filtering the results through pathway and interaction analyses, the researchers allowed the biology to point toward its own explanation rather than testing a single preconceived candidate. The trade-off is that proteomic datasets are noisy and context-dependent, which is why the team’s follow-up validation with staining and genetic methods is essential to the study’s credibility.

Cautious optimism is the appropriate posture. The work was conducted in mice with G0S2 overexpression, and while animal models are indispensable for establishing mechanism, the translation to human hepatocellular carcinoma requires demonstrating that the protein’s expression patterns in patient tumors correlate with disease behavior, that the BAX/Caspase3 mechanism operates in human liver cancer cells, and that pharmacologically modulating G0S2 can be done safely. The liver is a metabolically central organ, and a protein implicated in lipid handling and inflammation could carry off-target consequences if simply amplified systemically. The study, supported by the National Natural Science Foundation of China and regional science programs in Shandong Province, was approved by the ethics committee of Shandong Provincial Hospital and conducted under established laboratory animal welfare guidelines, underscoring the careful preclinical framework within which such findings must be interpreted.

Even so, the study offers something that the apoptosis and liver cancer fields genuinely need: a new, compact and mechanistically grounded candidate for tipping the balance of life and death in tumor cells. The BAX/Caspase3 pathway is one of the most conserved and well-characterized death circuits in biology, and any protein that can be shown to promote its activation becomes a potential lever for intervention, whether through gene-based therapies, small molecules that stabilize the protein, or strategies that mimic its downstream effects. The authors’ stated hope is that these findings may inform novel therapeutic strategies for treating hepatocellular carcinoma, a disease for which effective options remain painfully limited. As the paper moves through the scientific conversation, the next milestones will be replication in tumor models and human tissue, and the search for ways to translate a small protein’s apoptotic push into a clinical weapon against one of the world’s most lethal cancers.

Subject of Research: The role of the G0S2 protein in regulating apoptosis via the BAX/Caspase3 pathway in hepatocellular carcinoma

Article Title: Proteomic analysis reveals G0S2 as a potential apoptosis regulator in hepatocellular carcinoma

Article References: Wu, D., Zhang, X., Qiu, Y., Sun, W., Wang, Q., Yan, Y., Jing, M., Zhang, Z., Ma, S., & Sun, M. (2026). Proteomic analysis reveals G0S2 as a potential apoptosis regulator in hepatocellular carcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-16746-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16746-0

Keywords: G0S2, apoptosis, hepatocellular carcinoma, proteomics, BAX, Caspase3, FADD, liver cancer, cell death, BCL-2 family, therapeutic target, stress signaling

Long non-coding RNAs, or lncRNAs, are RNA molecules longer than roughly two hundred nucleotides that are transcribed from the genome but are not translated into proteins. For decades they were dismissed as transcriptional noise, yet it is now clear that many of them perform sophisticated regulatory duties inside cells. Some act as molecular scaffolds, bringing proteins together into functional complexes; others serve as guides, escorting proteins to specific DNA regions; still others function as sponges that soak up microRNAs. In cancer biology, lncRNAs have emerged as master regulators that can tilt the balance between cell growth and cell death, and between tissue stability and invasive spread. The Suzhou-led team set out to determine whether ATP6V1B1-AS1, an lncRNA named for its genomic neighbor in the ATP6V1B1 gene region, plays such a role in ovarian cancer.

To establish the clinical relevance of the molecule, the researchers first examined its expression pattern using data from The Cancer Genome Atlas, a large public repository of tumor genomic profiles, and then confirmed their observations in patient samples using reverse transcription quantitative polymerase chain reaction, a sensitive technique for measuring RNA abundance. The results were consistent: ATP6V1B1-AS1 was upregulated in ovarian cancer compared with normal tissue, and higher levels of the RNA were associated with worse prognosis in patients. This kind of correlation does not by itself prove causation, but it provided the essential starting hypothesis that the molecule might be doing something more than merely marking the presence of aggressive disease.

The team then moved from correlation to function. Using laboratory-grown ovarian cancer cells, they silenced ATP6V1B1-AS1 and measured the consequences with a battery of standard assays. Cell counting kit 8 assays, which quantify metabolic activity as a proxy for the number of living cells, showed that silencing the RNA slowed proliferation. Colony formation assays, which test whether single cells can divide repeatedly to form visible colonies, revealed a reduced capacity for sustained growth. Migration assays demonstrated that the cells also lost much of their ability to move, a property that is central to cancer’s ability to invade surrounding tissue and seed distant organs. Together, these in vitro experiments suggested that ATP6V1B1-AS1 is not a passive bystander but an active contributor to the malignant behavior of ovarian cancer cells.

To verify that these effects hold true in living organisms rather than only in culture dishes, the researchers turned to animal models. They used xenograft models, in which human ovarian cancer cells are implanted into immunodeficient nude mice, allowing human tumors to grow in a living host. They also established lung metastasis models to track the spread of cancer cells to secondary sites. When ATP6V1B1-AS1 was silenced, the mice developed smaller tumors and showed reduced metastatic colonization of the lungs. This in vivo confirmation is a critical step, because the three-dimensional architecture, nutrient gradients, and immune-free but otherwise complex environment of a living animal can expose dependencies that simple cell culture misses. The results indicated that the RNA’s influence on tumorigenesis and metastasis is robust enough to manifest in a whole organism.

With the functional role established, the central question became mechanistic: how does a non-coding RNA accomplish all of this? The team’s answer came from an unbiased search for binding partners. They performed an RNA pull-down experiment, in which the ATP6V1B1-AS1 molecule is used as bait to capture proteins that physically associate with it inside cells. The captured proteins were then identified by liquid chromatography coupled with tandem mass spectrometry, a technique that reads out the molecular weights and sequences of peptides to determine which proteins are present. Among the hits was MAP3K3, also known as MEK kinase 3, a mitogen-activated protein kinase kinase kinase that sits near the top of a signaling cascade controlling the p38 MAPK pathway, a route well known for transmitting stress and inflammatory signals into the cell nucleus.

The interaction between ATP6V1B1-AS1 and MAP3K3 was further validated by co-immunostaining and Western blotting, which confirmed that the RNA and the protein occupy overlapping cellular compartments and that their association has measurable biochemical consequences. Specifically, the binding of ATP6V1B1-AS1 to MAP3K3 facilitated the phosphorylation of p38 MAPK, the chemical modification that activates this pathway. Phosphorylation acts like a molecular switch: when p38 MAPK is phosphorylated, it relays signals that can promote cell survival, proliferation, and motility. Rescue experiments, in which the researchers restored pathway activity after silencing the RNA, demonstrated that the effects of ATP6V1B1-AS1 loss could be traced back through MAP3K3 to p38 MAPK, establishing a coherent signaling axis: ATP6V1B1-AS1 binds MAP3K3, MAP3K3 drives p38 MAPK phosphorylation, and the activated pathway propels ovarian cancer progression.

The significance of this work lies partly in its conceptual contribution to the growing recognition that lncRNAs can regulate cancer not only through gene expression but through direct protein interactions that modulate signaling cascades. Rather than changing how much MAP3K3 is produced, ATP6V1B1-AS1 appears to change what MAP3K3 does, enhancing its ability to activate p38 MAPK. This mode of action is attractive from a therapeutic standpoint because it suggests that disrupting the RNA-protein interaction, rather than blocking the kinase itself, might achieve a similar effect with potentially fewer off-target consequences. It also adds ATP6V1B1-AS1 to a short list of lncRNAs implicated in ovarian cancer, a disease that urgently needs new molecular targets given the limited treatment options available once platinum-based chemotherapy fails.

The research was supported by the Basic Research Medical Applied Basic Research Project in Suzhou City and the Suzhou Applied Basic Research Healthcare Science and Technology Innovation Guiding Project, and it received ethics approval from the Research Ethics Committee of Suzhou Municipal Hospital and the Animal Ethics and Welfare Committee of Nanjing Medical University. The authors, led by Yan Zhang, Ting Chen, and Meng Liu as co-first authors, with Shunyu Hou and Ting Fu as corresponding authors, declare no competing interests. As with any preclinical study, the path from these findings to the clinic will require further validation in larger patient cohorts and the development of strategies to safely interfere with the ATP6V1B1-AS1/MAP3K3/p38 MAPK axis in humans. Nevertheless, the study offers a clear mechanistic blueprint for how a single non-coding RNA can orchestrate tumor growth and metastasis, and it may provide a potential therapeutic target for ovarian cancer at a time when such targets are sorely needed.

Subject of Research: The role of the long non-coding RNA ATP6V1B1-AS1 in promoting ovarian cancer progression via the MAP3K3/p38 MAPK signaling pathway

Article Title: Long non-coding RNA ATP6V1B1-AS1 promotes ovarian cancer progression through targeting MAP3K3/p38 MAPK pathway

Article References: Zhang, Y., Chen, T., Liu, M., Zhang, Y., Zhou, L., Xi, X., Yu, L., Hou, S., & Fu, T. (2026). Long non-coding RNA ATP6V1B1-AS1 promotes ovarian cancer progression through targeting MAP3K3/p38 MAPK pathway. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02310-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02310-8

Keywords: ovarian cancer, long non-coding RNA, ATP6V1B1-AS1, MAP3K3, p38 MAPK, phosphorylation, metastasis, tumor progression, signal transduction, cancer biology, RNA-protein interaction, therapeutic target

The research, conducted by a team at Kangwon National University in South Korea and published in Cell Death Discovery, examined how stress granule formation influences tumor progression and metastasis in oral squamous cell carcinoma, or OSCC. The findings point to a specific molecular switch, the phosphorylation of a protein called eIF2α, as a central driver of the process. When that switch is suppressed, the study reports, stress granule formation drops, and with it the growth and metastatic burden of tumors in mouse models. The work adds oral cancer to a growing list of malignancies in which the integrated stress response appears to fuel, rather than restrain, disease.

To understand why this matters, it helps to consider what stress granules actually do. Under stress, cells activate kinases that phosphorylate eIF2α, the alpha subunit of a translation initiation factor. Phosphorylated eIF2α dampens global protein synthesis, and the messenger RNAs that would otherwise be translated are instead sequestered, along with RNA-binding proteins, into dense cytoplasmic droplets. Key markers of these structures include G3BP1, TIAR, and PABP, proteins that researchers use to identify stress granules under the microscope. In normal cells, this translational arrest conserves energy and prevents the accumulation of damaged or misfolded proteins. The system is meant to be reversible: when the stress passes, the granules dissolve and translation restarts.

Cancer cells, however, live in a state of chronic stress. Tumors outgrow their blood supply, creating regions of hypoxia, low oxygen tension that would kill most normal cells. They also face nutrient deprivation, acidic microenvironments, and assault from chemotherapy and radiation. In this context, the stress response can become a liability for the patient rather than a safeguard for the cell. Previous work in other cancers has implicated stress granules in tumor progression and metastasis, partly through their interactions with key signaling pathways, but their role in oral squamous cell carcinoma had remained poorly understood, despite growing scientific interest in the topic.

The Korean team began by comparing human tumor tissue with adjacent normal tissue. They found that markers of stress granules, including G3BP1, eIF2α, TIAR, and PABP, were significantly overexpressed in OSCC tissues compared with their normal counterparts. This observation established that the stress granule machinery is not merely present in oral cancer but is amplified, suggesting that tumor cells may rely on it more heavily than the healthy cells around them. Overexpression of these markers alone does not prove causation, but it set the stage for the functional experiments that followed.

Those experiments turned to mouse models built from OSCC cells that had been preconditioned with hypoxia, deliberately exposing the cells to low oxygen before implantation. The logic was to mimic the stressful conditions tumor cells encounter in a real growing tumor and to ask whether cells that had already mounted a stress response behaved differently afterward. In parallel, the researchers used a compound called ISRIB, an inhibitor of the integrated stress response that acts downstream of eIF2α phosphorylation, in mice subjected to sodium arsenite-induced stress. Sodium arsenite is a classic laboratory trigger of oxidative stress and a reliable inducer of stress granule formation, making it a useful tool for probing the pathway.

The results were striking. In both experimental settings, suppression of eIF2α phosphorylation was associated with reduced stress granule formation, reduced tumor growth, and a reduced metastatic burden. In other words, when the researchers blocked the molecular event that nucleates stress granules, the tumors not only grew more slowly but also spread less aggressively. Conversely, the study found that stress granule formation was elevated during hypoxia-induced stress, underscoring a stress-responsive regulatory mechanism in which the harsh conditions of the tumor microenvironment actively promote the assembly of these granules. Together, the data sketch a coherent chain of causation: hypoxia and other stresses trigger eIF2α phosphorylation, phosphorylation drives stress granule assembly, and the granules support the cellular programs that allow OSCC cells to proliferate and colonize distant sites.

Why would a structure designed to protect cells become an engine of metastasis? The authors and other researchers in the field point to the selective nature of stress granules. While global translation is arrested, certain messenger RNAs are preferentially stored within the granules and protected from degradation. Among the transcripts sheltered this way are often those encoding proteins that promote survival, invasion, and epithelial-to-mesenchymal transition, the process by which stationary epithelial cancer cells acquire the motility needed to invade surrounding tissue and enter the bloodstream. By acting as temporary warehouses for pro-metastatic messages, stress granules may allow tumor cells to stockpile the tools of aggression, releasing them for translation once the acute stress subsides. In this view, the granule is not merely a damage-control structure but a staging ground for the next phase of tumor progression.

The therapeutic implications are considerable. Oral squamous cell carcinoma is frequently diagnosed at advanced stages, and metastasis to cervical lymph nodes is one of the strongest predictors of poor outcome. Existing treatments, surgery, radiation, and chemotherapy, remain limited in their ability to control disseminated disease. If stress granule formation genuinely drives metastatic behavior, then the pathway offers a new target. ISRIB, the compound used in the mouse experiments, has attracted attention in recent years for its ability to blunt the integrated stress response, and the new findings suggest that agents with a similar mechanism could be explored as anti-metastatic therapies in oral cancer. The authors conclude that stress granules promote OSCC progression via eIF2α phosphorylation and might serve as a novel therapeutic target, a formulation that is deliberately cautious but clinically suggestive.

As with any preclinical study, important caveats apply. The evidence comes from human tissue comparisons and mouse models, and translating these findings into patients will require further work to confirm that the same mechanism operates in human tumors in real time, to identify which patient subsets have the highest stress granule activity, and to develop inhibitors with acceptable safety profiles. Suppressing a fundamental cellular stress pathway carries risks, since normal tissues also rely on the integrated stress response during injury and inflammation. Still, the study fills a genuine gap in the literature by connecting a well-characterized cellular stress mechanism to one of the most clinically feared behaviors of oral cancer. It also adds to a broader shift in cancer biology: the recognition that tumors are not just collections of mutated genes but ecosystems shaped by physical and chemical stress, and that the survival programs cells use to endure hardship can be turned against the organism that hosts them. For patients with oral squamous cell carcinoma, whose disease too often spreads before it can be stopped, the humble stress granule may prove to be an unexpected and consequential adversary.

Subject of Research: The role of stress-induced eIF2α phosphorylation and stress granule formation in promoting metastasis of oral squamous cell carcinoma

Article Title: Stress-induced eIF2α phosphorylation promotes tumor metastasis in oral squamous cell carcinoma

Article References: Kim, S., Park, S., Lee, Y., Park, G., & Choi, J. (2026). Stress-induced eIF2α phosphorylation promotes tumor metastasis in oral squamous cell carcinoma. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03412-4

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03412-4

Keywords: stress granules, eIF2α phosphorylation, oral squamous cell carcinoma, metastasis, integrated stress response, ISRIB, hypoxia, G3BP1, tumor progression, translational arrest, cancer biology, therapeutic target

Pathological cardiac hypertrophy is one of the most consequential maladaptations in medicine. Unlike the beneficial enlargement seen in athletes, whose hearts grow stronger in response to exercise, pathological hypertrophy arises from chronic stress such as hypertension, valve disease, or genetic mutations. The heart’s muscle cells, called cardiomyocytes, respond to sustained pressure overload by growing larger and thicker, initially compensating for the added workload. Over time, however, this remodeling distorts the heart’s architecture, impairs its ability to relax and fill with blood, and sets the stage for arrhythmias, fibrosis, and ultimately heart failure — a condition that remains among the leading causes of death worldwide. Understanding the transcriptional networks that decide whether the heart adapts gracefully or spirals into disease has therefore been a major goal of cardiovascular biology.

The research team, led by Xiao Zhang, Xiaopeng Liu, and colleagues, began with a clue from their earlier work: ZBED6 had been characterized as a key suppressor of skeletal muscle hypertrophy, raising the question of whether it played a similar role in the heart. Their first finding was clinical and striking. In myocardial tissue samples taken from patients with cardiac hypertrophy, ZBED6 was markedly reduced. This observation suggested that the protein’s decline might not be a bystander effect of disease but a contributing factor — a hypothesis the team then tested rigorously in animal models.

The decisive experiment came from pigs, whose cardiovascular systems closely resemble those of humans in size, anatomy, and physiology. When the researchers generated ZBED6-deficient pigs, the animals developed cardiac hypertrophy accompanied by diastolic dysfunction, meaning their hearts could not properly relax and fill between beats. Diastolic dysfunction is a hallmark of a common and difficult-to-treat form of heart failure, and its presence in the engineered pigs provided strong evidence that ZBED6 loss is sufficient to produce a clinically meaningful cardiac disease state, not merely a subtle molecular change.

To trace the mechanism, the team turned to integrative genomics. By combining transcriptomic profiling — which measures which genes are active — with ChIP-seq, a technique that maps where a transcription factor binds across the genome, they identified MEOX1 as a direct negative target of ZBED6. In other words, ZBED6 physically binds to regulatory regions of the MEOX1 gene and suppresses its expression. When ZBED6 is absent, this repression is lifted, and MEOX1 levels rise. The ChIP-seq data thus established a direct molecular link between the two proteins, ruling out indirect explanations for the correlation.

The consequences of MEOX1 upregulation proved to be far-reaching. The researchers found that elevated MEOX1 activates ERK1/2 signaling, a well-known intracellular pathway that transmits growth and stress signals from the cell surface to the nucleus. ERK1/2 has long been implicated in cardiac remodeling, but the new study places it downstream of a specific transcriptional switch, giving the pathway a defined position in the hierarchy of hypertrophy control. Critically, the team connected ERK1/2 activation to autophagy dysfunction. Autophagy is the process by which cells digest and recycle damaged proteins and organelles, and in cardiomyocytes it serves as an essential quality-control mechanism. The study shows that the ZBED6–MEOX1–ERK1/2 axis impairs this recycling system, and that the resulting autophagy failure is what drives the cardiomyocytes to enlarge pathologically.

Two lines of intervention evidence cemented the causal chain. First, when the researchers knocked down MEOX1 in ZBED6-deficient cardiomyocytes, ERK1/2 phosphorylation — the chemical modification that activates the pathway — dropped, and the hypertrophic growth of the cells was mitigated. Second, pharmacological inhibition of ERK1/2 restored autophagy and alleviated hypertrophy in ZBED6-depleted cardiomyocytes. Together, these experiments demonstrate that MEOX1 and ERK1/2 are not merely correlated with the disease process but are functionally required for it, and that the damage can be reversed by intervening at either node of the pathway.

The significance of the work lies in the assembly of these pieces into a coherent axis. ZBED6, a transcriptional repressor, normally holds MEOX1 in check; MEOX1, when unleashed, activates ERK1/2; ERK1/2, when activated, disrupts autophagy; and autophagy dysfunction pushes cardiomyocytes into pathological growth. Each step in this chain was verified independently, from the reduction of ZBED6 in human patient tissue to the rescue of diseased cells by pathway inhibition. The authors describe this as a previously unrecognized regulatory axis, and their collective findings define it as a potential therapeutic target for pathological cardiac hypertrophy.

The therapeutic implications are considerable. Current treatments for hypertrophic heart disease address symptoms and downstream consequences — lowering blood pressure, slowing heart rate, or managing heart failure once it develops — but few strategies target the transcriptional programs that initiate the maladaptive remodeling. A pathway that can be pharmacologically modulated at the ERK1/2 node, or potentially upstream at MEOX1, offers a more fundamental point of attack. The fact that ERK1/2 inhibitors already exist as a drug class, developed originally for oncology, suggests that repurposing or adapting such compounds for cardiac indications could be explored, although the pathway’s roles in other tissues would demand careful evaluation of safety and specificity.

The choice of the pig as a model organism also strengthens the translational relevance of the findings. Rodent models of cardiac disease have historically been invaluable but imperfect predictors of human cardiac physiology, and discrepancies between mouse and human heart biology have complicated drug development. Pigs, with hearts comparable in size and function to human organs, bridge that gap, and the demonstration that ZBED6 deficiency produces hypertrophy and diastolic dysfunction in this species lends weight to the conclusion that the same axis operates in humans — particularly given the concordant reduction of ZBED6 observed in patient myocardial tissue. As research moves from this foundational characterization toward therapeutic exploration, the ZBED6–MEOX1–ERK1/2 axis stands as a newly charted route into the molecular heart of a devastating disease, one that may eventually allow clinicians to intervene before the heart’s compensatory growth becomes its own undoing.

Subject of Research: The role of the ZBED6–MEOX1–ERK1/2 signaling axis in pathological cardiac hypertrophy and autophagy dysfunction

Article Title: ZBED6 deficiency drives pathological cardiac hypertrophy through MEOX1–ERK1/2–dependent autophagy dysfunction

Article References: Zhang, X., Liu, X., Pan, R., Liu, H., Xiao, J., Leng, X., Zhang, H., Pan, D., Duan, S., & Wu, J. (2026). ZBED6 deficiency drives pathological cardiac hypertrophy through MEOX1–ERK1/2–dependent autophagy dysfunction. PLOS Genetics, 22(10), e1012329. https://doi.org/10.1371/journal.pgen.1012329

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012329

Keywords: ZBED6, cardiac hypertrophy, MEOX1, ERK1/2 signaling, autophagy, heart failure, diastolic dysfunction, transcription factor, cardiomyocytes, PLOS Genetics, ChIP-seq, therapeutic target

The RBM family is defined by a shared structural module: the RNA recognition motif, a compact domain of roughly ninety amino acids folded into a four-stranded beta sheet packed against two alpha helices. This domain binds short stretches of RNA, typically through aromatic residues that stack against the bases, and most RBM proteins carry multiple copies of it, often connected by flexible linkers that allow tandem domains to recognize longer or composite RNA elements. Many members also harbor auxiliary domains, such as zinc fingers, OCRE motifs, or arginine-rich regions, that extend their binding repertoire or recruit interaction partners. Structural studies, including nuclear magnetic resonance analyses of RBM10’s OCRE-containing domain and crystallographic work on RBM5’s RNA-binding surface, have revealed how these proteins achieve specificity despite the modest selectivity of any single RRM domain. The result is a versatile toolkit: RBM proteins can clasp pre-messenger RNAs, mature transcripts, long noncoding RNAs, and even ribosomal RNA, positioning them to regulate nearly every step of the RNA lifecycle.

Among the best-characterized family members are RBM5 and RBM10, which the review describes as tumor suppressors. Both proteins function as components of the U2 small nuclear ribonucleoprotein particle, engaged with intron branch sites on chromatin, where they steer the splicing machinery toward particular exon choices. Their tumor-suppressive influence is vividly illustrated by their control of NUMB alternative splicing: RBM5, RBM6, and RBM10 differentially regulate which NUMB isoform is produced, and the resulting isoform balance determines whether cancer cells proliferate or restrain themselves. In lung adenocarcinoma, RBM10 loss promotes proliferation and metastasis through a feedback loop involving microRNA-224-5p and p53, and the protein also restrains the RAP1/AKT/CREB signaling pathway. RBM10 mutations, which are frequent in lung adenocarcinoma, have been proposed as negative prognostic and predictive markers, and a specific C761Y mutation in cholangiocarcinoma generates oncogenic ASPM isoforms that activate beta-catenin signaling. Recent work has even exploited this vulnerability therapeutically: RBM10-deficient lung adenocarcinoma cells show heightened sensitivity to agents that induce DNA replication stress, opening a synthetic-lethal strategy against tumors that have lost this suppressor.

RBM5 itself displays a strikingly context-dependent personality. In colorectal cancer, it suppresses proliferation, metastasis, and glycolysis by stabilizing the messenger RNA of the phosphatase and tensin homolog, PTEN, a master brake on growth signaling. It also recruits the factor MGC32805 in a sandwich mode to induce a novel FAS neoantigen, switching the death receptor’s properties in a way that may sensitize tumors to immune attack. Yet in acute myeloid leukemia, RBM5 plays the villain, activating the oncogenic protein HOXA9 and supporting leukemic growth. This duality, the same protein acting as friend in one tissue and foe in another, recurs throughout the family and underscores a central theme of the review: RBM proteins cannot be labeled simply as oncogenes or suppressors. Their function depends on the RNA landscape of the cell, the signaling pathways in play, and the selective pressures of the tumor microenvironment.

A second axis of RBM-mediated cancer regulation runs through m6A, the most abundant internal chemical modification of messenger RNA. RBM15 and its paralog RBM15B are core components of the m6A writer complex, the machinery that deposits methyl groups onto adenosines across the transcriptome. By recognizing the histone mark H3K79me2, RBM15B guides selective m6A modification of messenger RNAs and enhances oncoprotein translation in MLL-rearranged leukemia, a finding reported in the EMBO Journal in 2026 that links chromatin state directly to RNA modification patterns. In triple-negative breast cancer, RBM15 drives cell growth by stimulating serine and glycine metabolism, while in cervical cancer it promotes epithelial-mesenchymal transition through m6A modification of the EZH2 transcript and supports stemness by stabilizing the long noncoding RNA HEIH. RBM15 also enhances paclitaxel resistance in triple-negative breast cancer by methylating TNFSF9 and polarizing tumor-associated macrophages toward an immunosuppressive M2 state, connecting RNA modification to both drug resistance and the immune microenvironment.

Other family members exert their influence through equally inventive mechanisms. RBM3, a cold-shock-inducible protein, suppresses stemness remodeling of prostate cancer in the bone microenvironment by modulating m6A on CTNNB1 messenger RNA, halts the cell cycle of cutaneous squamous cell carcinoma through the PI3K/AKT pathway, and has repeatedly been associated with favorable prognosis and cisplatin sensitivity in epithelial ovarian cancer and muscle-invasive bladder cancer. RBM38, meanwhile, is a key lieutenant of the p53 tumor-suppressor network: it stabilizes the p53-MDM2 loop in hepatocellular carcinoma, and its genetic ablation promotes lymphomagenesis in the context of mutant p53 by downregulating PTEN. RBM47 restrains renal cell carcinoma by interacting with the long noncoding RNA HOXB-AS1 and acts as an anti-oncogene in colorectal cancer, yet in pancreatic cancer it promotes proliferation and immune evasion by upregulating PDIA6, and in nasopharyngeal carcinoma it drives tumorigenesis through multiple pathways. RBM45 reprograms lipid metabolism in hepatocellular carcinoma via Rictor and the acyl-CoA synthetases ACSL1 and ACSL4, and stabilizes the glutamine transporter ASCT2 through phosphorylation to fuel tumor progression.

The therapeutic implications of this biology are beginning to crystallize. The most advanced example involves RBM39, a related RNA-binding protein that can be degraded by molecular-glue compounds such as indisulam and E7820, which recruit the DCAF15 ubiquitin ligase. A 2024 study in npj Precision Oncology showed that an RBM39-degrader induces synthetic lethality in cancer cells deficient in homologous recombination repair, suggesting a rational combination with PARP inhibitors or platinum chemotherapy. For the RBM family proper, a first-in-class small-molecule inhibitor of the eIF4E-RBM38 complex has been developed; by disrupting this interaction, the compound enhances translation of wild-type p53 and suppresses tumor growth, validating protein-protein interfaces involving RBM proteins as druggable targets. A synthetic peptide called Pep8 achieves a similar effect by camouflaging the same interface. These proof-of-concept successes matter because the RNA recognition motif has long been considered difficult to drug, its shallow RNA-binding grooves resisting conventional small-molecule approaches.

The review also highlights how RBM proteins intersect with clinical decision-making beyond drug targets. RBM3 expression levels correlate with chemosensitivity in ovarian and bladder cancers, potentially guiding platinum-based treatment choices. RBM10 mutation status may stratify patients with non-small-cell lung cancer, flagging tumors with distinct vulnerabilities and therapy responses. RBM11 serves as a prognostic biomarker in ovarian cancer, RBM19 promotes prostate cancer progression under docetaxel treatment through the SNHG21/PIM1 axis, and RBMX contributes to sorafenib resistance in hepatocellular carcinoma by stabilizing the long noncoding RNA BLACAT1. RBM38, conversely, reverses sorafenib resistance by promoting the tumor-suppressive lncRNA GAS5. As liquid biopsy platforms for circulating tumor cells mature, RNA-binding protein signatures detected in blood may eventually complement tissue-based diagnostics, though the review stops short of claiming clinical readiness for such applications.

What emerges from this synthesis is a portrait of a protein family whose complexity mirrors that of cancer itself. The same RBM protein can suppress one tumor while feeding another, can be drugged in one context and mimicked in another, and can act through splicing, m6A methylation, messenger RNA stability, translation, or long noncoding RNA scaffolding depending on circumstance. The Qingdao University team argues that disentangling these context-dependent roles, through systematic mapping of RNA targets, structural dissection of binding domains, and careful correlation with patient outcomes, is the essential next step. If that effort succeeds, the RBM family could yield a generation of biomarkers that predict treatment response and therapeutic strategies that exploit the very RNA-processing dependencies cancers have built into themselves. For now, the review stands as both a map of what is known and a catalog of what remains to be tested, from the branch sites of chromatin-bound introns to the methylated transcripts that decide a tumor’s fate.

Subject of Research: The roles of the RBM RNA-binding protein family in cancer occurrence, progression, and therapy

Article Title: RBM protein family: Focusing on the occurrence, progression and treatment of cancer

Article References: Zhang, H., Zheng, W., Li, L., Geng, C., Wang, Y., Zhang, J., Sun, Y., Zhang, X., & Li, B. (2026). RBM protein family: Focusing on the occurrence, progression and treatment of cancer. Medical Oncology, 43(11), Article 322. https://doi.org/10.1007/s12032-026-03439-8

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03439-8

Keywords: RBM proteins, RNA-binding proteins, alternative splicing, m6A methylation, tumor suppressor, oncogene, RBM10, RBM15, RBM38, therapeutic target, biomarker, cancer

Extrachromosomal circular DNA is exactly what the name suggests: small rings of DNA that exist outside the chromosomes, looping free of the linear genome. Unlike chromosomal DNA, these circles can carry intact gene fragments and regulatory elements, and because they replicate independently of the normal cell cycle, they can be amplified rapidly in numbers. That property makes eccDNA a potent engine of oncogene overexpression, a mechanism that has been implicated in drug resistance in several cancers, including notoriously amplified circles carrying the MYC oncogene in neuroblastoma and other tumors. Yet in ovarian cancer, the interplay between eccDNA and the epigenetic machinery that controls gene activity has remained poorly charted territory.

The epigenetic machinery in question centers on histone deacetylases, or HDACs, enzymes that remove acetyl chemical groups from histone proteins around which DNA is wound. When histones are highly acetylated, DNA is more accessible and genes are more active; HDACs strip those acetyl groups away, tightening chromatin and silencing genes. In many cancers, HDAC activity is dysregulated, contributing to the abnormal silencing of tumor suppressors and the miswiring of gene-control networks. HDAC inhibitors, including the drug panobinostat, also known by its code name LBH589, were designed to reverse that silencing and restore normal gene expression patterns in tumor cells.

Panobinostat is a broad-spectrum HDAC inhibitor that has been tested in various hematologic and solid malignancies. The new study set out to ask a question that is often overlooked in drug development: what happens to the eccDNA landscape when a tumor is treated with an epigenetic drug? The answer, according to the team’s experiments, is that the drug does far more than simply reactivate silenced genes. It induces a significant remodeling of the eccDNA population within ovarian cancer cells, with a notable enrichment of circles derived from messenger RNA genes and from long noncoding RNAs, a class of regulatory RNA molecules with their own roles in cancer biology.

To connect this eccDNA remodeling to gene activity, the researchers integrated two powerful genome-wide datasets. The first came from RNA sequencing, which measures the complete set of RNA transcripts produced by the cells and therefore reveals which genes are switched up or down under treatment. The second came from chromatin immunoprecipitation sequencing, or ChIP-seq, targeted at HDAC3, one of the key histone deacetylase enzymes. ChIP-seq identifies the precise genomic locations where HDAC3 binds, marking the genes it directly regulates. By overlaying these maps with the eccDNA data, the team identified a set of 52 oncogenes that are linked to eccDNA, bound by HDAC3, and consistently upregulated by panobinostat treatment.

That convergence of three independent molecular signals, eccDNA presence, HDAC3 binding, and treatment-induced upregulation, is what gives the finding its weight. It suggests that the drug’s inhibition of HDAC3 does not uniformly suppress oncogenic potential. Instead, in at least a subset of genes, blocking HDAC3 appears to coincide with an adaptive activation program in which oncogenes carried or associated with circular DNA become more highly expressed. The authors describe this as an adaptive oncogenic response, a kind of molecular counterpunch thrown by the tumor as the epigenetic pressure of the drug takes hold.

The clinical relevance of these 52 genes was tested using survival analysis across multiple cancer cohorts. The team found that alterations in these oncogenes correlated with worse disease-free survival, meaning that patients whose tumors carried changes in these genes tended to remain cancer-free for shorter periods after treatment. This kind of population-level correlation does not prove causation on its own, but it flags the gene set as a meaningful marker of aggressive disease and provides a rationale for digging deeper into individual members of the group.

One member stood out. LMO2, a gene encoding a transcriptional regulator best known for its roles in blood cell development and, historically, as a gene disrupted in certain leukemias, emerged from the analysis as a novel oncogene in ovarian cancer. The mechanistic work behind this claim is technically detailed but conceptually clear. Supplementary analyses showed that panobinostat increases the levels of H3K27ac, an acetyl mark on histone H3 that signals active regulatory regions, at the promoter-proximal regions of the LMO2 gene, without altering HDAC3 binding at those same sites. In other words, the drug does not move HDAC3 off the DNA; it changes the chemical balance of chromatin in a way that favors LMO2 activation.

Functional experiments reinforced the picture. In TOV-112D, an ovarian cancer cell line used in the study, inhibiting HDAC3 with drugs or knocking the enzyme down with interfering RNAs both led to increased LMO2 expression. Conversely, when the researchers knocked LMO2 down, the cells became more sensitive to panobinostat. That last result is the most consequential: it implies that LMO2 upregulation is not merely a byproduct of treatment but a functional contributor to reduced drug sensitivity. A tumor that can ramp up LMO2 in response to HDAC inhibition may thereby cushion itself against the drug’s effects, and removing that cushion restores vulnerability.

The broader significance of the study lies in its demonstration that epigenetic therapy and the eccDNA layer of cancer genetics are deeply intertwined. HDAC-associated epigenetic regulation, the authors conclude, is connected to eccDNA-linked oncogene activation, and this connection may modulate how ovarian cancer patients respond to HDAC inhibitors. For clinicians, the work suggests a potential combination strategy: pairing HDAC inhibitors with approaches that suppress LMO2 or its downstream effects could prevent the adaptive escape that otherwise undermines treatment. For researchers, the study provides a template for integrating Circle-seq, RNA-seq, and ChIP-seq data to find similar vulnerabilities in other tumor types. The work, supported by funding from the National Natural Science Foundation of China and provincial programs, was conducted with approval from the Animal Welfare Committee of Fudan University Shanghai Cancer Center, and the authors report no competing interests. As the field moves toward therapies that target the nonchromosomal genome, LMO2 now stands as a concrete, testable target in the fight against ovarian cancer’s most stubborn defense mechanisms.

Subject of Research: The interplay between extrachromosomal circular DNA, HDAC3-mediated epigenetic regulation, and oncogene activation in ovarian cancer

Article Title: Integration of eccDNA and transcriptomic landscapes uncovers LMO2 as a therapeutic target in ovarian cancer

Article References: Han, T., Yan, Q., Bu, H., Gan, Y., Shen, X., Li, K., Guan, L., Dong, W., Li, P., Zhao, M., Zhou, X., Gao, B., & Hao, Q. (2026). Integration of eccDNA and transcriptomic landscapes uncovers LMO2 as a therapeutic target in ovarian cancer. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02296-3

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02296-3

Keywords: eccDNA, ovarian cancer, LMO2, HDAC3, panobinostat, epigenetics, oncogene, drug resistance, transcriptomics, ChIP-seq, therapeutic target, Journal of Ovarian Research

The clinical backdrop makes the finding urgent. Surgical resection remains the only curative option for cholangiocarcinoma, yet because early-stage disease produces few symptoms, only 30 to 40 percent of patients are candidates for an operation. Even among those who undergo complete tumor removal, recurrence is common and the five-year overall survival rate falls below 40 percent. Current guidelines recommend six months of adjuvant capecitabine after curative surgery, while for advanced disease the combination of cisplatin and gemcitabine, known as CisGem, stands as the first-line standard of care. But chemotherapy resistance is high, and patients receiving CisGem experience progression-free survival and overall survival of only about 8.0 and 11.7 months, respectively. Targeted agents and immunotherapies have begun to reshape the landscape, with the IDH-1 inhibitor ivosidenib demonstrating activity in the ClarIDHy phase III trial for patients with IDH-1-mutant tumors, and pembrolizumab indicated for tumors deficient in mismatch repair proteins or showing high microsatellite instability. Still, the field suffers from a shortage of specific biomarkers and effective therapeutic targets.

CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1, or ENTPD1, is a membrane-bound enzyme that hydrolyzes extracellular ATP and ADP into anti-inflammatory adenosine. It is normally expressed in organs such as the bladder, brain, lung, spleen, thymus, and placenta, primarily on endothelial and immune cells. Its abundance varies dramatically across immune populations: more than 90 percent of B lymphocytes, monocytes, and neutrophils in peripheral blood carry it, roughly 20 to 30 percent of CD4-positive T cells including memory T cells and regulatory T cells express it, fewer than 5 percent of CD8-positive T cells do, and only 2 to 5 percent of natural killer cells display it on their surface. Crucially, CD39 has been found overexpressed in a range of solid tumors, including colorectal cancer, lung cancer, pancreatic cancer, head and neck cancer, and chronic lymphocytic leukemia, and high expression has been linked to poor outcomes in clear cell renal cell carcinoma, non-small-cell lung cancers, hepatocellular carcinoma, ovarian carcinoma, and gastric cancers. Its role in cholangiocarcinoma, however, had remained unexplored until now.

To fill that gap, the researchers began with a systematic search for genes that behave abnormally in bile duct cancer. RNA sequencing of 12 paired tumor and adjacent non-tumor samples from their institution identified 3,383 upregulated and 3,258 downregulated genes. They then cross-referenced these results with RNA-seq data from the TCGA dataset, comprising 9 pairs, and a GEO dataset, also 9 pairs, and found 21 genes abnormally expressed across all three cohorts. Ten upregulated candidates were selected for validation by quantitative reverse transcription PCR in 24 paired tumor and normal tissue samples. Only one survived the scrutiny: CD39 was significantly upregulated in tumor tissue, and both RT-qPCR and western blotting confirmed that its levels were especially elevated in tumors from patients with lymph node metastasis.

The clinical significance became even clearer when the team turned to immunohistochemistry in a much larger cohort of 180 cholangiocarcinoma patients. Consistent with the molecular data, CD39 was highly expressed in tumor tissue compared with adjacent non-tumor tissue, with a P value below 0.001. Aberrant expression was also observed in patients with lymph node metastasis compared with those without, again at P < 0.001. Survival analysis revealed that patients with high CD39 expression had significantly worse overall survival, with P < 0.001. High expression correlated with a higher rate of lymph node metastasis, P = 0.007, and with more advanced TNM stage, P = 0.004. Most importantly, multivariable Cox proportional hazards regression established CD39 expression as an independent prognostic factor for overall survival, meaning its predictive power held even after accounting for other clinical variables.

Having established the correlation, the researchers moved to causation. They first profiled CD39 expression across human cholangiocarcinoma cell lines, finding it low in the RBE line and high in TFK-1, and used these two lines for gain- and loss-of-function experiments. Cell Counting Kit-8 assays showed that knocking down CD39 inhibited proliferation, while overexpressing it significantly boosted proliferative capacity. Transwell assays told a parallel story for motility: silencing CD39 suppressed the migratory and invasive abilities of TFK-1 cells, whereas forcing its expression enhanced migration and invasion in RBE cells. The pattern extended into living organisms. In cell-line-derived xenograft models using immunodeficient B-NDG mice, tumor volume and weight rose significantly when CD39 was overexpressed and fell when it was knocked down. The number of metastatic nodules in the liver increased in the overexpression group and decreased in the knockdown group, directly implicating CD39 in the metastatic spread of the disease.

The mechanistic breakthrough came from co-immunoprecipitation followed by mass spectrometry. Applying stringent filters, including confidence scores of at least 100 in the mass spectrometric assays and absence from corresponding anti-sense control groups, the team identified nine candidate proteins that physically interact with CD39. Western blotting confirmed that one of them, Annexin A2, or ANXA2, specifically binds CD39. ANXA2 is a calcium-mediated phospholipid-binding protein known to regulate cell survival and communication with the extracellular environment, and it has been implicated in the metastasis of gastric, colorectal, prostate, and breast cancers. Notably, the interaction with CD39 did not change the total amount of ANXA2 in the cells; instead, it altered its phosphorylation state. Knocking down CD39 suppressed phosphorylation of ANXA2 at the tyrosine 24 residue, a modification previously linked to malignant transformation, epithelial-mesenchymal transition, tumor invasion, and metastasis.

Downstream of ANXA2, the team traced the signal into two well-known cancer-promoting programs. Gene Set Enrichment Analysis of RNA-seq data from both tumor tissue and cell lines showed that the PI3K/AKT pathway and the epithelial-mesenchymal transition, or EMT, process were significantly influenced in cases with high CD39 expression. Western blotting confirmed the bioinformatics: knocking down CD39 reduced the phosphorylation of PI3K, AKT, and mTOR at the S2448 site without changing their total protein levels, while overexpression enhanced their phosphorylation. CD39 levels also reshaped the EMT machinery, with knockdown lowering the expression of Claudin-1, Twist-1, Vimentin, and N-cadherin while raising E-cadherin, and overexpression producing the opposite pattern. The decisive proof came from a rescue experiment in which the researchers mutated the Tyr24 site of ANXA2, substituting alanine for tyrosine. This single amino acid change reversed nearly everything CD39 had done: the proliferative boost measured by CCK-8, the migratory and invasive gains seen in transwell assays, the EMT marker shifts, and the PI3K/AKT phosphorylation all collapsed once the phosphorylation site was eliminated.

The authors are candid about the limitations of their work. The study is retrospective, and the prognostic role of CD39 will need validation in a prospective multi-center cohort. The number of samples and cell lines was modest, and larger cohorts would strengthen the statistical power and generalizability of the findings. It also remains unclear exactly how the CD39/ANXA2 axis influences cholangiocarcinoma progression, and how CD39 modulates ANXA2 phosphorylation and the downstream signaling cascades requires further investigation. Even so, the convergence of evidence from human tissue, cell culture, animal models, and mechanistic biochemistry makes a compelling case. CD39 stands out as both a biomarker that could identify patients at highest risk and a therapeutic target whose blockade might starve bile duct tumors of a key growth and spread pathway. For a cancer with so few options, that dual promise is a rare and welcome development.

Subject of Research: The role of CD39 expression in the progression, metastasis, and prognosis of cholangiocarcinoma

Article Title: The aberrant expression of CD39 is associated with the dismal outcome of patients with cholangiocarcinoma

Article References: Zheng, B., Shen, S., Wang, J., Sun, W., Wan, W., Liu, J., Zhang, D., Ni, X., Suo, T., Liu, H., Ni, X., & Liu, H. (2025). The aberrant expression of CD39 is associated with the dismal outcome of patients with cholangiocarcinoma. Clinical Cancer Bulletin, 4(1), Article 1. https://doi.org/10.1007/s44272-025-00028-0

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00028-0

Keywords: CD39, cholangiocarcinoma, ANXA2, PI3K/AKT signaling, EMT, phosphorylation, prognostic biomarker, biliary tract cancer, ENTPD1, metastasis, immunohistochemistry, therapeutic target

The calcium-sensing receptor, or CaSR, was first cloned from bovine parathyroid glands and has long been recognised as a central guardian of calcium homeostasis. It sits in the cell membrane and detects even small fluctuations in extracellular calcium, triggering intracellular signalling cascades that keep blood calcium within a narrow, life-sustaining range. Although the liver is not a calciotropic organ, calcium signalling within hepatocytes influences glucose and lipid metabolism, bile secretion, mitochondrial activity, and fundamental cellular processes such as growth, differentiation, movement and programmed cell death. Disturbances in intracellular calcium have even been implicated in the progression of non-alcoholic fatty liver disease towards liver cancer, and CaSR has been linked to cholestasis, ischemia-reperfusion injury, insulin resistance and genetic susceptibility to hepatocellular carcinoma.

What makes CaSR particularly intriguing in cancer biology is its dual personality. In some tumours, including parathyroid and gastrointestinal cancers, the receptor appears to restrain growth and act as a tumour suppressor. In others, such as intrahepatic cholangiocarcinoma, breast cancer, osteosarcoma and Leydig cell tumours, CaSR activation instead promotes proliferation and metastatic behaviour. Genetic polymorphisms in the CaSR gene, particularly at the rs17251221 locus, have been shown to influence susceptibility to hepatocellular carcinoma and treatment outcomes. Yet the precise mechanisms by which the receptor operates in the most common form of primary liver cancer had remained poorly characterised, leaving an important gap in understanding that the new study set out to fill.

The stakes are considerable. Hepatocellular carcinoma accounts for roughly ninety percent of primary liver cancers, and liver cancer overall ranks as the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related death worldwide. Patients diagnosed at an early stage can benefit from surgical resection, but those presenting with intermediate or advanced disease typically rely on chemotherapy or immunotherapy regimens whose clinical benefits remain constrained. Long-term survival is limited for a substantial proportion of patients, and the restricted array of validated therapeutic targets has made the search for new strategies an urgent medical priority.

In the new research, the team first confirmed that CaSR is present in two widely used human hepatocellular carcinoma cell lines, HepG2 and SMMC-7721, using immunofluorescence microscopy, quantitative reverse transcription PCR and Western blotting. Notably, SMMC-7721 cells expressed significantly higher levels of the receptor protein than HepG2 cells. The researchers then pharmacologically inhibited the receptor with NPS-2143, a well-characterised negative allosteric modulator of CaSR, and measured the consequences across a battery of functional assays. The results were striking: NPS-2143 reduced the proliferation of both cell lines in a concentration-dependent manner, with effects becoming particularly pronounced at 48 and 72 hours after treatment. The drug also lowered expression of PCNA, a proliferation marker, alongside reducing CaSR mRNA and protein levels.

Beyond proliferation, the researchers examined whether CaSR blockade could blunt the metastatic machinery of liver cancer cells, a critical question given that metastasis drives recurrence and poor outcomes in hepatocellular carcinoma. Using Transwell migration and invasion assays, they showed that treated cells migrated and invaded far less efficiently than untreated controls. At the molecular level, the expression of MMP-2 and MMP-9, matrix metalloproteinases that remodel the extracellular matrix and enable cells to breach tissue barriers, dropped significantly after NPS-2143 exposure. These findings suggest that CaSR supports the invasive potential of hepatocellular carcinoma cells at least partly by sustaining the production of these matrix-degrading enzymes.

The study also uncovered a pro-death effect. Flow cytometric analysis using Annexin V and propidium iodide staining revealed a marked increase in apoptotic cells after 24 hours of NPS-2143 treatment. Western blotting illuminated the underlying mechanism: the anti-apoptotic protein Bcl-2 was downregulated, while the pro-apoptotic protein Bax and cleaved caspase-3, the executioner enzyme of programmed cell death, were upregulated. This coordinated shift in the balance of apoptotic regulators indicates that blocking CaSR actively pushes liver cancer cells towards self-destruction rather than merely slowing their division.

To trace the signalling pathways responsible, the researchers turned their attention to the mitogen-activated protein kinases, or MAPKs, which govern proliferation, apoptosis, migration and survival in cancer. NPS-2143 treatment increased the phosphorylation of p38 MAPK, a pathway often associated with apoptotic signalling and tumour growth suppression, while simultaneously reducing the phosphorylation of ERK1/2, a cascade frequently hijacked by cancers to drive proliferation and invasion. Total levels of both proteins were unaffected, pointing to a specific change in pathway activation rather than protein abundance. The team then confirmed these results genetically: silencing CaSR with siRNA reproduced every pharmacological effect, curbing growth, migration and invasion while raising apoptotic rates and producing the same p38 and ERK1/2 phosphorylation changes.

Crucially, the anti-tumour effects extended into living animals. In female BALB/c nude mice bearing HepG2 xenografts, intraperitoneal injection of NPS-2143 at 10 micromoles per kilogram every 48 hours for 12 days significantly reduced tumour size and weight compared with vehicle controls, without any measurable loss of body weight. Immunohistochemistry of excised tumours showed reduced CaSR immunoreactivity and a sharp decline in Ki67 staining, indicating diminished cell division. Western blotting of tumour tissue mirrored the in vitro findings, with increased p-p38 and Bax and decreased p-ERK, MMP-9 and Bcl-2. Because NPS-2143 is primarily a functional antagonist rather than a transcriptional inhibitor, the authors interpret the reduced CaSR expression after treatment as a secondary feedback change rather than direct repression of the gene. To address the influence of sex, since hepatocellular carcinoma occurs more frequently in males, an independent experiment using Huh7 cells in male nude mice reproduced the tumour-shrinking effect, strengthening confidence in the result across cell lines and sexes.

The authors are careful to acknowledge the limitations of their work. Two cell lines cannot capture the full molecular diversity of hepatocellular carcinoma, the animal cohorts were modest in size, and immunodeficient mice cannot recapitulate the complex immune microenvironment of human liver cancer. Potential off-target interactions of NPS-2143 also cannot be entirely dismissed, and CRISPR-based knockout experiments would provide firmer genetic validation. Nevertheless, the convergence of pharmacological and genetic evidence, in vitro and in vivo, paints a coherent picture: CaSR supports the proliferation, motility and survival of hepatocellular carcinoma cells through ERK1/2 and p38 MAPK signalling, and its blockade reverses these malignant behaviours. If future studies in immunocompetent models and patient-derived systems confirm these findings, drugs that silence this calcium sensor could open a genuinely new front against one of the world’s deadliest cancers.

Subject of Research: The role of the calcium-sensing receptor in hepatocellular carcinoma progression and its inhibition as a potential therapy

Article Title: Inhibition of Calcium‐Sensing Receptor Suppresses Malignant Behaviours of Human Hepatocellular Carcinoma

Article References: Liu, T., Xu, W., Gao, Q., Ngwa Adeline, N., Yang, Q., He, D., Tao, Y., Sun, J., Gu, J., Shi, H., Aschner, M., Ye, Y., Chen, J., & Lu, R. (2026). Inhibition of Calcium‐Sensing Receptor Suppresses Malignant Behaviours of Human Hepatocellular Carcinoma. Journal of Cellular and Molecular Medicine, 30(19), Article e71389. https://doi.org/10.1111/jcmm.71389

Image Credits: AI Generated

DOI: 10.1111/jcmm.71389

Keywords: calcium-sensing receptor, hepatocellular carcinoma, liver cancer, NPS-2143, MAPK signalling, p38 MAPK, ERK1/2, apoptosis, cell migration, xenograft model, MMP-9, therapeutic target